白细胞介素-22作为创伤相关急性肾损伤的新型治疗
研究在大鼠失血性休克与复苏模型中评估重组人IL-22蛋白融合人Fc片段(IL-22:Fc)对创伤相关急性肾损伤的作用。将平均动脉压降至40 mm Hg并维持30分钟,随后用乳酸林格液复苏至平均动脉压60 mm Hg并维持30分钟。治疗组(n=8)在复苏开始时给予150 μg/kg IL-22:Fc,与假注射组比较。两组均出现急性肾损伤,但治疗组复苏结束时血尿素氮和肌酐较低,尿白蛋白浓度较低(0.39 vs. 0.12 μg/mL,p=0.02),外髓质中性粒细胞明胶酶相关脂质运载蛋白较低。作者认为IL-22:Fc保护肾脏且似乎选择性作用于外髓质,可能成为创伤患者急性肾损伤的新型疗法。
要点
- 在大鼠失血性休克与复苏模型中,复苏开始时给予IL-22:Fc 150 μg/kg,治疗组复苏结束时血尿素氮和肌酐低于假注射组。
- 治疗组尿白蛋白浓度为0.39 vs. 0.12 μg/mL(p=0.02),低于对照组。
- 外髓质中性粒细胞明胶酶相关脂质运载蛋白水平在治疗组较低;皮质肾小球(1,005 vs. 1,457 AU,p=0.41)和内髓质(5,670 vs. 5,885 AU,p=0.16)无差异。
- 治疗组肾皮质小管中性粒细胞明胶酶相关脂质运载蛋白水平更高(2,420 vs. 3,541 AU,p=0.02)。
- 治疗组肾脏磷酸化信号转导与转录激活因子3水平未升高,作者认为其保护作用似乎不由信号转导与转录激活因子3介导。
适用人群与场景
- 创伤相关急性肾损伤的大鼠模型(Sprague-Dawley大鼠,失血性休克与复苏模型)。
处置流程与药物剂量
- 治疗组(n=8)在复苏开始时给予IL-22:Fc 150 μg/kg,与假注射组比较;原文未写明给药途径。
研究设计与关键结果
- 研究类型:大鼠失血性休克与复苏模型研究;治疗组n=8,与假注射组比较。
- 模型制作:平均动脉压降至40 mm Hg并维持30分钟,随后用乳酸林格液复苏至平均动脉压60 mm Hg并维持30分钟。
- 两组均出现急性肾损伤(以血尿素氮和血清肌酐衡量),治疗组复苏结束时血尿素氮和肌酐较低。
- 尿白蛋白浓度:治疗组0.39 vs. 对照组0.12 μg/mL(p=0.02)。
- 外髓质中性粒细胞明胶酶相关脂质运载蛋白水平在治疗组较低;皮质肾小球1,005 vs. 1,457 AU(p=0.41),内髓质5,670 vs. 5,885 AU(p=0.16),无差异;肾皮质小管治疗组更高(2,420 vs. 3,541 AU,p=0.02)。
- 治疗组肾脏磷酸化信号转导与转录激活因子3水平未升高。
证据类型、等级与局限
- 证据类型:动物实验(大鼠失血性休克与复苏模型)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为IL-22:Fc可能成为创伤患者急性肾损伤的新型疗法;该结论来自大鼠模型,原文未给出临床推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Treatment for acute kidney injury (AKI) after trauma remains primarily supportive. While interleukin (IL)-22 is known to decrease cell death and stimulate regeneration in the kidney, its potential as a therapeutic in trauma-relevant AKI is unknown. IL-22:Fc is a recombinant human IL-22 protein combined with a human Fc immunoglobulin to increase serum half-life. We hypothesized that IL-22:Fc would mitigate AKI in a trauma-relevant rat model of hemorrhagic shock and resuscitation (H/R).
METHODS: Sprague-Dawley rats were anesthetized, and femoral arteries were cannulated. Mean arterial pressure was reduced to 40 mm Hg by withdrawing blood and kept there for 30 minutes. Animals were then resuscitated with intravenous lactated Ringer's solution to a mean arterial pressure of 60 for an additional 30 minutes. Treated animals (n = 8) received 150 μg/kg of IL-22:Fc at the start of resuscitation and compared with sham injected. Laboratories were drawn at baseline and end of resuscitation.
RESULTS: Both groups demonstrated AKI as measured by blood urea nitrogen and serum creatinine, while treated animals had lower blood urea nitrogen and creatinine at the end of H/R. In addition, IL-22:Fc-treated animals had lower urinary albumin concentration (0.39 vs. 0.12 μg/mL, p = 0.02). Furthermore, neutrophil gelatinase-associated lipocalin levels, a marker of AKI, measured in the outer medulla were lower in treated animals. Neutrophil gelatinase-associated lipocalin levels measured in the cortex glomeruli (1,005 vs. 1,457 AU, p = 0.41) and inner medulla (5,670 vs. 5,885 AU, p = 0.16) were not different. Neutrophil gelatinase-associated lipocalin levels were higher in the tubular cortex for treated rats (2,420 vs. 3,541 AU, p = 0.02). Phosphorylated signal transducer and activator of transcription 3 levels were not higher in the kidney of treated rats.
CONCLUSION: IL-22:Fc protects the kidneys after H/R and appears to act selectively on the outer medulla. This beneficial effect does not appear to be mediated by signal transducer and activator of transcription 3, as shown in other organ systems. IL-22:Fc may be a novel therapy for AKI in trauma patients.
参考来源
- Taghavi S, Mills C, Shaheen F, et al. Interleukin-22 as a novel therapy for trauma relevant acute kidney injury. J Trauma Acute Care Surg. 2025. PMID: 40455011. doi:10.1097/TA.0000000000004655
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。